Opinion & insight

A space for healthcare professionals to freely share and discuss their opinions and experiences. Please contact us if you’d like to contribute.

Latest insight from the epgonline team

The Asthma Report

ERS 2018 | Day 4 Highlights

Posted 2 days ago

A look at two sessions from the ERS Congress dealing with devices for the management of asthma and an in-depth look at some of the allergic responses to asthma.

Lauren McCracken

EAACI hot topics: Hereditary angioedema (HAE)

Posted 2 months ago

For many the fear of the unknown is a daunting thought, but particularly so for patients with HAE. Left untreated, this disease causes unpredictable recurrent severe swelling, typically of the limbs, face, intestinal tract and airway.

Alex Keen

EULAR 2018 – Biosimilars: the future of rheumatology?

Posted 3 months ago

EULAR's Annual European Congress of Rheumatology aims to encourage innovation and collaboration across all aspects of rheumatology, something that is particularly well illustrated by biologics and their more affordable counterpart, biosimilars. Could they unlock the door to accessible, life-changing treatment for millions more?

Lauren McCracken

EAACI hot topics: Allergen specific immunotherapy (AIT)

Posted 3 months ago

When should AIT be used to treat your patients with allergies? Is it right for every allergy? And do we really know the long-term effects of this treatment? This blog highlights some of the talking points surrounding AIT discussed at this year’s EAACI Congress.

Allen Wellings

EAACI 2018 ‒ Allergy management and the smart technology revolution

Posted 3 months ago

The theme of this year’s EAACI congress is ‘innovations for allergy’, so we started thinking what smart technologies, if any, are in development or on the market that could address the allergy epidemic?

Alex Keen

ILC 2018 – Targetable pathways in liver disease: from identification to clinical application

Posted 5 months ago

A number of studies from the speakers at this year's ILC Basic Science Seminar are discussed here, focusing on targetable pathways in liver disease, covering pathway identification, potential drug targets and their clinical application.

Dr Elizabeth Angier

What’s Allergy got to do with it?

Posted 1 year ago

Experiences of an allergy and immunology congress - a short blog (by a primary care physician).

Liam Farrell

Bad smells are good

Posted 1 year ago

Delicacy is not a virtue in this job.

Antia Veiga Feijoo

Clinical Features and Treatment Of Acute Asthma Exacerbations

Posted 3 years ago

This post discusses clinical assessment and treatment of patients with acute asthma exacerbations.

Yuli Pramana

Choosing Between Endoscopic Sclerotherapy And Endoscopic Ligation For Esophageal Varices

Posted 3 years ago

Endoscopic Sclerotherapy (ES) and Endoscopic Ligation (EL) were accepted in the treatment of esophageal varices bleeding in patients with liver cirrhosis. EL seemed to be superior to ES. If EL was difficult then ES should be performed.

WHAT'S ON THE HORIZON?

Our Clinical Steering Group

Horizons, led by a team of experts from our Clinical Steering Group, is a series of scientific articles which take a deep dive into the emerging trends in the healthcare landscape, kickstarting a dialogue about how treatments and strategies should be best implemented for the benefit of patients. Click below to find out more.

What's on the horizon?

Marshall Pearce

How close are we to a disease-modifying treatment for Alzheimer’s?

Posted 9 months ago

Alzheimer’s disease is a snowballing problem, one that is currently without a convincing solution. The progressive decline in cognitive function seen in patients with Alzheimer’s disease is associated strongly with plaques formed of amyloid beta in the brain, creating neurofibrillary tangles and leading to neuronal destruction. While some treatments improve cognition in the short-term, current therapeutic options are unable to modify or slow the disease process.

Penny Staton

Improving non-alcoholic steatohepatitis care – is the finishing line in sight?

Posted 11 months ago

An intense race is going on right now in non-alcoholic steatohepatitis (NASH) research. A number of significant players within the pharmaceutical and biotechnology sectors are competing to develop the first major therapeutic advance in treatment for this neglected condition. But should we consider it more of a relay race? Could improved diagnosis, disease assessment and even combination therapy be the key to victory over this increasingly prevalent disease?

Marshall Pearce

Left ventricular assist devices – A viable therapeutic option for heart failure?

Posted 1 year ago

Alongside a pharmacological strategy to aid myocardial recovery, LVADs may prove to have a significant role to play in the ever-growing problem of heart failure. Although LVADs are not new onto the scene, the advance of technology – smaller, more efficient devices with better reliability and potentially transcutaneous power transfer – means we may be on the cusp of seeing many more deployed to tackle heart failure.

Marshall Pearce

Cancer immunotherapies

Posted 1 year ago

It was the winner of the 1908 Nobel prize for medicine, Paul Ehrlich, who is first credited with discussing the concept of a “magic bullet”, able to target specific cells without damaging healthy tissue. With the advent of immunotherapy, as well as antibody-drug conjugates, we are beginning to realise this vision.

Marshall Pearce

Antibody-drug conjugates (ADCs)

Posted 1 year ago

Over the past couple of decades, there have been advances in a class of drugs which for a long time was purely theoretical: antibody-drug conjugates (ADCs). The concept underlying ADCs is elegant – what if it were possible to ‘target’ particular groups of cells with a cytotoxic agent, rather than exposing every cell of the body to it?

Opinion archive